The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Inclusion Criteria: * Provision of signed and dated informed consent form * Adults (18 years or older) * Cognitively impaired adults are not excluded (i.e. will be included in the study) * Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs) * EEG consistent with focal or generalized epilepsy * Patients must have \>4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month. * Patients can be on \>/= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation * Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study. Exclusion Criteria * Patients \<18 years of age * Pregnant women * Women that are breast feeding * Patients who had \>21 days of seizure freedom in the last year. * Patients with a history of status epilepticus within 3 months of screening * Patients with a history of alcoholism of drug misuse within the last 2 years * Unstable medical illness * Serious or imminent suicidal or homicidal risk * Patients with cardiovascular disease * Patients with schizophrenia * Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage * Patients that are immobile i.e. wheel chair bound, bed ridden individuals * Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.)